The Food and Drug Administration (FDA) advises the public against the purchase and use of the unnotified cosmetic product with brand/product name DOUBLE J GOSHI ASHITABA + GUYABANO [ANGELICA KESKEI + SOURSOP] BEAUTY SOAP.

FDA post-marketing surveillance (PMS) activities have verified that the abovementioned cosmetic product has not gone through the verification process of the agency and has not been issued the proper authorization in the form of acknowledged cosmetic notification. Pursuant to Republic Act No. 9711, otherwise known as the “Food and Drug Administration Act of 2009”, the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use, promotion, advertising or sponsorship of health products without the proper authorization from FDA is prohibited.

Accordingly, because said unnotified cosmetic product has not gone through the verification process of the FDA, the agency cannot guarantee its quality and safety. The use of such violative product may pose potential health hazards to the consuming public which may come from ingredients that are not allowed to be part of a cosmetic product or from the contamination of heavy metals such as lead and mercury. The use of substandard and possibly adulterated cosmetic product may result to adverse reactions including but not limited to skin irritation, itchiness, anaphylactic shock and organ failure.

In light of the above, the public is advised not to purchase the aforementioned violative product. Moreover, the public is also advised to be vigilant against cosmetic products that might not be duly notified with FDA. Consumers can check if a cosmetic product has been notified with FDA by making use of the embedded Search feature of the FDA website accessible at www.fda.gov.ph.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unnotified cosmetic products, kindly e-mail us via report@fda.gov.ph, call us at the Center for Cosmetics Regulation and Research (CCRR) hotline (02) 857-1984, or utilize our online reporting facility, eReport, at www.fda.gov.ph/ereport.        

Dissemination of the information to all concerned is requested

Accesible through the FDA website.